Q-omics provides the consensus-scored PUF60 profile across patient tissues and cancer cell-line models. PUF60 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PUF60 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, PUF60 protein abundance shows 31,498 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, COAD, and GBM as cancer lineages where PUF60 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PUF60 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PUF60 survival associations across molecular data types. PUF60 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PUF60 RNA expression–survival associations across cancer types. High PUF60 expression shows unfavorable associations in ACC, LIHC, UVM, LUAD and HNSC, but favorable associations in LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PUF60 RNA expression.
This table summarizes PUF60 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PUF60. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PUF60 shows higher tumor expression in COAD, HNSC, LIHC, LUSC, LUAD and BLCA. The COAD box plot shows higher PUF60 RNA expression in tumor versus normal tissue (log2 FC = +1.322, t-test p < 0.001).
This table shows molecular features associated with PUF60 in patient tissues and cancer cell lines. In patient samples, PUF60 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PUF60 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
